BIOMAT Database Logo BIOMAT Database Logo

The prevalence of hepatitis B surface antigen (HBsAg), anti-hepatitis B surface (anti-HBs) and anti-hepatitis B core (anti-HBc) in patients with acquired immuno-deficiency syndrome (AIDS). 1990

E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Department of Medicine, College of Health Science, University of Nairobi, Kenya.

Forty one consecutive patients (24 males and 17 females) with AIDS had their blood assayed for HBsAg, anti-HBs and anti-HBc by Reversed Passive Haemagglutination (RPHA), Passive Haemagglutination (PHA) and Enzyme Linked Immunosorbent Assay (ELISA) techniques respectively. 5 (12.2%) were found positive for HBsAg. 10 (24.4%) for anti-HBs and 31 (75.6%) for anti-HBc. 32 (78%) out of 41 patients with AIDS had serological evidence of exposure to hepatitis B virus (HBV). The prevalence of HBsAg found in this study is not different from what has been found in the Kenyan community without AIDS, while that of anti-HBs is much lower than what has been reported in the general community.

UI MeSH Term Description Entries
D007630 Kenya A republic in eastern Africa, south of ETHIOPIA, west of SOMALIA with TANZANIA to its south, and coastline on the Indian Ocean. Its capital is Nairobi. Republic of Kenya
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006510 Hepatitis B Antibodies Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens. Anti-Australia Antigens,Anti-HBAg,Anti-Hepatitis B Antigens,Anti HBAg,Hepatitis B Virus Antibodies,Anti Australia Antigens,Anti Hepatitis B Antigens,Antibodies, Hepatitis B,Antigens, Anti-Australia,Antigens, Anti-Hepatitis B,B Antibodies, Hepatitis,B Antigens, Anti-Hepatitis,HBAg, Anti
D006512 Hepatitis B Core Antigens The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion. HBcAg,Hepatitis B Core Antigen
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor.
September 2021, Hepatology forum,
E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Hepatitis B antigen (HBSAg) and/or antibodies (anti-HBS and anti-HBC) in fulminant hepatitis: pathogenic and prognostic significance.
January 1976, Gut,
E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Hepatitis-B surface antigen (HBsAg) and antibody (anti-HBs) prevalence among laboratory and nonlaboratory hospital personnel.
September 1977, Southern medical journal,
E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Hepatitis B virus infection in Taiwan with reference to anti-HBc versus HBsAg and anti-HBs.
September 1980, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Response to hepatitis B vaccine in HBsAg/anti-HBs negative and anti-HBc positive subjects.
January 2000, Scandinavian journal of infectious diseases,
E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Molecular characterization of hepatitis B virus surface antigen mutants in Singapore patients with hepatocellular carcinoma and hepatitis B virus carriers negative for HBsAg but positive for anti-HBs and anti-HBc.
December 2002, Journal of gastroenterology and hepatology,
E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation.
June 2018, Clinical immunology (Orlando, Fla.),
E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Hepatitis B virus surface antigen (HBsAg) and antibody (anti-HBs) forming immune complexes in fulminant hepatitis.
January 1999, Revista da Sociedade Brasileira de Medicina Tropical,
E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Hepatitis B virus screening in contacts of blood donors with antibodies against core protein (anti-HBC), but without surface antigen (HBsAg).
March 2006, Memorias do Instituto Oswaldo Cruz,
E O Ogutu, and E O Amayo, and F Okoth, and G N Lule
Evaluation of assay methods for hepatitis B surface (HBsAg) antigen and its antibody (anti-HBs) in viral hepatitis B (VHB)-HBsAg-positive.
November 1978, Medical microbiology and immunology,
Copied contents to your clipboard!